Cargando…

Lersivirine: a new NNRTI active across HIV-1 subtypes with a unique resistance profile

Detalles Bibliográficos
Autores principales:	Mori, J, Westby, M, Tawadrous, M, van der Ryst, E, Charles, C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The International AIDS Society 2010
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112864/ http://dx.doi.org/10.1186/1758-2652-13-S4-O49

Ejemplares similares

No effect of a single supratherapeutic dose of lersivirine, a next-generation NNRTI, on QTc interval in healthy subjects
por: Vourvahis, M, et al.
Publicado: (2010)

Multiple dosage forms of the NNRTI microbicide dapivirine: product development and evaluation
por: Romano, Joseph
Publicado: (2006)

The characteristics of the HIV subtype B epidemic in Slovenia
por: Lunar, Maja M, et al.
Publicado: (2014)

Hepatotoxicity in patients co-infected with HIV and tuberculosis while receiving NNRTI-based antiretroviral regimen and rifampicin
por: Mankhatitham, W, et al.
Publicado: (2010)

Neutralization of tier-2 viruses and epitope profiling of plasma antibodies from subtype-C HIV-1 infected north Indians; implications for MPER directed HIV-1 neutralization
por: Andrabi, Raiees, et al.
Publicado: (2012)

Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-naive HIV-positive patients
por: Gatell, Josep M, et al.
Publicado: (2014)

Immunodynamics of Th17 cells in HIV-1 subtype ‘C’ infection
por: Vajpayee, Madhu, et al.
Publicado: (2012)

HIV-1 subtype C viruses rapidly develop K65R
por: Wainberg, Mark A, et al.
Publicado: (2006)

Patient reported outcome instruments used in clinical trials of HIV-infected adults on NNRTI-based therapy: a 10-year review
por: Simpson, Kit N, et al.
Publicado: (2013)

OA03-06 LB. Unique stimulatory properties of myeloid dendritic cells in individuals with "elite" HIV-1 control
por: Huang, J, et al.
Publicado: (2009)

Development of subtype specific RealTime PCR based growth competition assay for assessing the replication fitness of drug resistant viruses of Indian HIV-1 clade C
por: Hingankar, Nitin K, et al.
Publicado: (2014)

Parallel dysregulation across psychoimmunological and cardiovascular response systems in HIV+ outpatients
por: Temoshok, Lydia R, et al.
Publicado: (2006)

Beneficial HLA-mediated viral polymorphisms on the transmitted virus additively influence disease progression in HIV-1, subtype C infection
por: Ntale, RS, et al.
Publicado: (2012)

The changing face of HIV resistance; HIV drug resistance north and south — what's next?
por: Schapiro, J
Publicado: (2010)

Full-length genome sequences of Estonian HIV-1 CRF06 and Eastern-European subtype A1 recombinant forms
por: Avi, Radko, et al.
Publicado: (2014)

Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI/NNRTI resistant viruses
por: Pham, Hanh T., et al.
Publicado: (2016)

A unique approach to compensation and its verification
por: Dimmick, Ian
Publicado: (2015)

Identification of the Critical Sites of NNRTI-Resistance in Reverse Transcriptase of HIV-1 CRF_BC Strains
por: Huang, Yang, et al.
Publicado: (2014)

Increasing proportions of HIV-1 non-B subtypes and of NNRTI resistance between 2013 and 2016 in Germany: Results from the national molecular surveillance of new HIV-diagnoses
por: Hauser, Andrea, et al.
Publicado: (2018)

HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa
por: Kityo, Cissy, et al.
Publicado: (2017)

Cardiac magnetic resonance differentiates subtypes in bicuspid aortic valve and reveals various frequencies of aortic stenosis among subtypes
por: Wassmuth, Ralf, et al.
Publicado: (2012)

Microbiological profile and multidrug resistant bacteria in pneumonia
por: Slavcovici, Adriana, et al.
Publicado: (2013)

International perspectives on adherence and resistance to HIV antiretroviral therapy
por: Bangsberg, D
Publicado: (2010)

Vaccine-induced ADCC-mediating antibodies target unique and overlapping envelope epitopes
por: Pollara, J, et al.
Publicado: (2012)

Cost-effectiveness of 2NRTI+NNRTI versus 2NRTI+PI as the initial cART regimen
por: Aragão, F, et al.
Publicado: (2010)

Distinct gene expression profiles associated with the susceptibility of pathogen-specific CD4+ T cells to HIV-1 infection
por: Hu, H, et al.
Publicado: (2012)

Interactions of different drug resistance mutations in HIV Reverse Transcriptase in defining patterns of drug resistance
por: Wainberg, Mark A
Publicado: (2011)

Novel resistance mechanism of HIV-1 To peptide fusion inhibitors
por: Gupta, Nidhi, et al.
Publicado: (2006)

HIV Gag and PR: partners in resistance to protease and maturation inhibitors
por: Nijhuis, Monique
Publicado: (2011)

Tailored therapies based upon tumor subtype biology
por: Perou, CM
Publicado: (2005)

Low-Frequency NNRTI-Resistant HIV-1 Variants and Relationship to Mutational Load in Antiretroviral-Naïve Subjects
por: Gupta, Shaili, et al.
Publicado: (2014)

Carbohydrate restriction uniquely benefits metabolic syndrome and saturated fat metabolism
por: Volek, Jeff S
Publicado: (2012)

A unique case of fractured titanium implant after sternal resection
por: Yordanov, D, et al.
Publicado: (2013)

Feasibility of testing and detection of HIV-1 drug resistance in proviral DNA
por: Booth, Clare L, et al.
Publicado: (2014)

Uncontrolled chronic rhinosinusitis with and without polyps is predicted by T cell subtype
por: Kosak, Tanja Soklic, et al.
Publicado: (2015)

Long-term probability of detecting drug-resistant HIV in patients starting antiretroviral therapy within the first year of HIV infection
por: Lodi, S, et al.
Publicado: (2010)

OA06-03. Dynamics of CTL epitope escape and reversion in an African subtype C cohort
por: Schaefer, M, et al.
Publicado: (2009)

Analysis of the HIV resistance related HLA dRB1 restricted CD4+ T cell epitopes among Indian HIV patients
por: Christy, H Jemmy, et al.
Publicado: (2014)

Incidence of CXCR4 tropism and CCR5-tropic resistance in treatment-experienced participants receiving maraviroc in the 48-week MOTIVATE 1 and 2 trials
por: Jubb, Becky, et al.
Publicado: (2019)

S10.4d A unique clinical appearance of Candida auris infection in Japan
por: Umeyama, Takashi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_v759eon6mu99ql2ut6ogjsagr1